PPARG and amyotrophic lateral sclerosis: Our findings are in agreement with the effects observed with PPARγ agonists in models of ischemic and hemorrhagic stroke, and CNS disease including Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis and Parkinson's disease [54]–[56].